EUROPEAN COMMISSION
JOINT RESEARCH CENTRE

Directorate F – Health and Food
Disease Prevention

Annual Declaration of Interests[1] (DoI) form
(v2, 01 July 2026)

European Commission initiative on Lung Cancer (EC-LuC)

Please answer each of the questions below.
If the answer to any of the questions is "Yes"[2], please complete the corresponding fields, describing the circumstances, as appropriate.

If you do not submit a filled-in and signed DoI form, please consider that you cannot be involved in the EC-LuC activities.
If you do not disclose relevant activities of interest for the EC-LuC, your role may be revised.

[1] According to EC's Decision C(2016) 3301 establishing horizontal rules on the creation and operation of Commission expert groups, Articles 2(4) and 10, each member of an expert group has to complete a DoI form
https://ec.europa.eu/transparency/documents-register/detail?ref=C(2016)3301&lang=en

[2] Answering "Yes" to the questions on this form does not automatically limit your participation in the EC-LuC activities. Your answers will be reviewed to determine whether you have a conflict of interest (CoI) (*i.e.* any interest that may affect, or may reasonably be perceived to affect, an expert's objectivity and independence).

Name and Surname:	

Activities (2021 - 2025)	**Yes/No**	**Period (From - To)**	**Information**	**Details**
1. Do you have current investments[3] in a legal entity[4] with an interest related to lung cancer which either: • **has a value of more than 10.000 EUR, or** • **entitles you to a voting right of 5% or more?**	Yes ☐ No ☒	MM/YYYY – MM/YYYY	If 'yes', please specify: • Name of entity; • Place; • Type of entity: public, private.	[Please describe your role.]

[3] **Investments** refer to stocks, bonds, stock options, other securities as well as to commercial business interests (*e.g.*, proprietorships, partnerships, joint ventures, board memberships, controlling interest in a company).

[4] **Legal entity** refers to any commercial business, industry association, consultancy, research institution or other enterprise whose funding is significantly derived from commercial sources. It also includes independent own commercial businesses, law offices, consultancies or similar.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
2. Within the past 5 years, were you employed (remunerated or non-remunerated post) or have you had any other professional relationship with a legal entity or any other body, with an interest related to lung cancer? **A. Employment**	Yes ☐ No ☒	MM/YYYY – MM/YYYY	If 'yes', please specify: • Name of the entity; • Place; • Type of entity: public, private; • Received amounts for remunerated activities.	[Please describe your role.]
B. Consultancy, including advisory activities	Yes ☐ No ☒	MM/YYYY – MM/YYYY	If 'yes', please specify: • Name of the entity; • Place; • Type of the entity: public, private; • Received amounts for remunerated activities.	[Please describe your role.]
C. Non-remunerated post	Yes ☒ No ☐	01/2023 – ongoing	• Member of the Swedish National Lung Cancer Clinical Guideline Group; • public entity	Member of the Swedish National Lung Cancer Clinical Guideline Group as primary care representative (non-remunerated).

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
D. Legal representation[5]	Yes ☐ No ☒	MM/YYYY – MM/YYYY	If 'yes', please specify: • Name of the entity; • Place; • Type of the entity: public, private;	[Please describe your role.]
3. Regarding research related to lung cancer within the past 5 years: **A. Have you been an investigator in research studies on lung cancer?**	Yes ☒ No ☐	02/2025 – ongoing	Principal Investigator (PI) of STEADY-CAN. Nemlander et al., 2025 (Eur J Epidemiol): "The Stockholm Early Detection of Cancer Study (STEADY-CAN): rationale, design, data collection, and baseline characteristics for 2.7 million participants. Investigator in Nemlander et al., 2022 (PLoS One): Predictive modelling of lung cancer using an adaptive symptom e-questionnaire at Karolinska University Hospital. This work forms the scientific basis for ongoing doctoral research. Supervisor of PhD project (2025–present): Symptoms and biomarkers for early lung cancer detection, as a continuation and extension of the findings from the above study.	

[5] **Legal representation** refers to the representation of natural or legal persons through other persons in accordance with national law. For example, the president of a company is the legal representative of that company.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
B. If yes, for the aforementioned research studies, did you receive support[6]?	Yes ☒ No ☐	MM/YYYY – MM/YYYY	Swedish Research Council, (Sweden – public) Establishment grant, 11,100,000 SEK, 2025–2031 "A blood test-based risk model for early cancer detection in primary care" Region Stockholm (Stockholm, Sweden – public) Grant funding 2024–2026, approx. 1,200,000 SEK Robert Lundberg Memorial Foundation (Stockholm, Sweden – private, non-profit foundation) Grant funding 2024, 75,000 SEK Research grant (main-applicant) Einar Belvén Foundation (Stockholm, Sweden – private, non-profit foundation) SEK 4 million total over 4 years (2026–2029) Research grant (co-applicant) Einar Belvén Foundation (Stockholm, Sweden – private, non-profit foundation) SEK 3.5 million total over 3 years (2023–2025)	[Please mention the title of the studies you refer to.]

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
4. Do you have membership in national or international organisations[7], including committees, working groups, collaborative platforms, managing bodies or scientific advisory bodies or any decision making bodies with an interest in lung cancer?	Yes ☒ No ☐	MM/YYYY – MM/YYYY	National Coordinator for Early Cancer Detection, Regional cancer centre in collaboration (RCC) (2024–present). Member, National Clinical Guideline Group for Lung Cancer, RCC (2023–present).	Actively participating in the development and revision of national clinical guidelines for lung cancer, with a specific responsibility to safeguard and represent the primary care perspective, including involvement in decision-making processes regarding recommendations and standards of care.
5. Do you have intellectual property rights (IPR)[8] related to lung cancer?	Yes ☐ No ☒	MM/YYYY – MM/YYYY	Please specify the title of the IPR.	[Please describe the IPR.]

[6] **Support** refers to research support (i.e. grants, collaborations, sponsorships) as well as to non-monetary support (equipment, facilities) and other type of support (i.e. honoraria for being a speaker, holding a training).

[7] **Organisation** refers to a governmental, international or non-profit organisation.

[8] **Intellectual property rights** refer to patents, trademarks, or copyrights (including pending applications) as well as proprietary know-how in a substance, technology or process.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
6. Within the past 5 years: **A. Have you provided any expert opinion or testimony in the field of lung cancer, for a legal entity or other body as part of a regulatory, legislative or judicial process?**	Yes ☐ No ☒	MM/YYYY – MM/YYYY	Please mention the activity.	[Please describe the activity.]
B. Have you held an office or other position, paid or unpaid, where you represented interests or defended an opinion in the field of lung cancer?	Yes ☒ No ☐	MM/YYYY – MM/YYYY	Primary care representative, RCC lung cancer guideline group (2023–present).	Representing the primary care perspective in the development and revision of the Swedish National Lung Cancer Clinical Guidelines.
7. Do any of your immediate family members[9] have direct interests related to lung cancer that could undermine your independence?	Yes ☐ No ☒	MM/YYYY – MM/YYYY	Please mention the interest.	[Please describe the interest.]

[9] **Immediate family members** refer to family members and relatives (spouse, parents, children, brothers and sisters, irrespective of whether they live at the same address or not) or other persons under the care of the members of the household of the expert.

Activities (2021 - 2025)	Yes/No	Period (From - To)	Information	Details
8. Within the past 5 years, did you take part in other activities with interests related to lung cancer?	Yes ☒ No ☐	MM/YYYY – MM/YYYY	Organised and delivered professional education in primary care on early cancer detection (since 2017).	Educational activities for healthcare professionals focusing on early cancer detection and diagnostic pathways in primary care.

Notes:

If you declared any direct interests of your immediate family members, it is your responsibility to inform them about how data on their interests are collected and published[10] before you send the DoI form to the Joint Research Centre (JRC), EC.

After submission of this form, you need to inform the JRC in case of any new activity during the course of the year by sending an e-mail as soon as possible at: JRC-CANCER-POLICY-SUPPORT@ec.europa.eu.

☒ **I hereby declare the information disclosed in this form is true and complete to the best of my knowledge.**

☒ **I agree my DoI form to be publicly available on the EC's web-hub on cancer screening and care, during the EC-LuC membership[11].**

☒ **I am informed that my personal data are stored, processed and published by the EC in accordance with Regulation (EU) 2018/1725[12].**

Name and Surname: **Elinor Nemlander** **Date:** **22-07-2026**

Signature: **Place: Stockholm, Sweden**

[10] Personal data processing including the DoI
https://ec.europa.eu/dpo-register/detail/DPR-EC-00656

[11] Note: Technical measures are in place to ensure that search engines do not index the content from the DoI form.

[12] Protection of individuals with regard to the processing of personal data
https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32018R1725

Signature page

This document has been electronically signed using eduSign.

eduSign

Electronically signed by
Susanna Elinor Nemlander

Date and time of signature
2026-07-22 11:10 GMT

Authenticated by
Karolinska Institutet